Strong Animal Health Business Growth
Animal Health business grew sales by 14% in the quarter, led by vaccines growth of 22% and MFA and other growth of 15%.
Performance Products Segment Growth
Performance Products segment grew by 27%, driven by increased demand for ingredients used in personal care products.
Increased Guidance for Fiscal Year 2025
Updated guidance for fiscal year 2025 shows expected mid-single-digit growth in revenue and a leveraged P&L on a stand-alone basis.
Successful Acquisition of Zoetis' Medicated Feed Additive Business
The acquisition closed successfully, and preliminary estimates for the Zoetis portfolio for the 8-month period in fiscal year 2025 include net sales of approximately $200 million with an adjusted EBITDA margin of approximately 20%.
Strong Financial Performance
First quarter adjusted EBITDA increased by $12 million or 64% versus the prior year, reflecting significant growth in adjusted net income and adjusted diluted EPS.